Barbara Frigerio

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/813656/barbara-frigerio-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11 papers	136 citations	6 h-index	11 g-index
12 ext. papers	180 ext. citations	6.8 avg, IF	2.05 L-index

#	Paper	IF	Citations
11	Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody. *Cells*, **2020**, 9,	7.9	3
10	Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 125	12.8	36
9	Anti-PSMA I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 326	12.8	9
8	A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy. *Frontiers in Immunology*, **2019**, 10, 2514	8.4	5
7	Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. *MAbs*, **2018**, 10, 1084-1097	6.6	8
6	Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. *Oncotarget*, **2017**, 8, 10919-10930	3.3	14
5	Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen. *Immunology Letters*, **2015**, 168, 105-10	4.1	8
4	A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. *European Journal of Cancer*, **2013**, 49, 2223-32	7.5	42
3	Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4. *PLoS ONE*, **2011**, 6, e22081	3.7	5
2	Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection. *Journal of Translational Medicine*, **2009**, 7, 101	8.5	4
1	Soil persistence of DNA from transgenic poplar. *Environmental Biosafety Research*, **2009**, 8, 79-86		2